Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ait Therapeutics Inc (AITB)

Ait Therapeutics Inc (AITB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 55,444
  • Shares Outstanding, K 10,581
  • Annual Sales, $ 7,720 K
  • Annual Income, $ -6,560 K
  • 60-Month Beta -0.26
  • Price/Sales 7.01
  • Price/Cash Flow N/A
  • Price/Book 11.45
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.85
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 06/25/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.22
  • Number of Estimates 1
  • High Estimate -0.22
  • Low Estimate -0.22
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +38.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.60 +13.91%
on 07/08/19
6.16 -14.90%
on 06/21/19
+0.01 (+0.19%)
since 06/12/19
3-Month
4.46 +17.49%
on 04/16/19
6.25 -16.15%
on 05/09/19
+0.51 (+10.78%)
since 04/12/19
52-Week
3.11 +68.48%
on 12/27/18
6.25 -16.15%
on 05/09/19
+1.25 (+31.33%)
since 07/11/18

Most Recent Stories

More News
CORRECTING and REPLACING - AIT Therapeutics Reports Financial Results for Fiscal Fourth Quarter and Year-End 2019 Results

Announces name change to

AITB : 5.24 (+2.34%)
AIT Therapeutics Reports Financial Results for Fiscal Fourth Quarter and Year-End 2019 Results

Announces name change to

AITB : 5.24 (+2.34%)
AIT Therapeutics Announces Study Published in Journal of Cystic Fibrosis

AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions...

AITB : 5.24 (+2.34%)
AIT Therapeutics Presents Data at the 2019 American Thoracic Society Conference in Dallas, TX

AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions...

AITB : 5.24 (+2.34%)
AIT Therapeutics Announces Oral and Poster Presentations at the International Society for Aerosols in Medicine 2019 Congress in Montreux, Switzerland

AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions,...

AITB : 5.24 (+2.34%)
AIT Therapeutics to Present Data at the 2019 American Thoracic Society Conference in Dallas, TX

AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions...

AITB : 5.24 (+2.34%)
AIT Therapeutics Announces Uplisting to the Nasdaq Capital Market

AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions...

AITB : 5.24 (+2.34%)
AIT Therapeutics to Demonstrate NO Generator and Delivery System at Pediatric Academic Societies Meeting in Baltimore, MD on April 27-30

AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions...

AITB : 5.24 (+2.34%)
Recro Pharma Falls as FDA Denies Approval to Pain Candidate

FDA issues complete response letter for Recro Pharma's (REPH) marketing application for pain candidate, meloxicam, for the second time.

ALKS : 19.87 (-1.19%)
OCUL : 2.93 (-11.75%)
REPH : 17.46 (+0.06%)
AITB : 5.24 (+2.34%)
Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan

Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.

PFE : 36.93 (-0.32%)
AERI : 19.05 (-0.94%)
AITB : 5.24 (+2.34%)
ASRT : 0.72 (-1.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade AITB with:

Business Summary

Beyond Air Inc. is a clinical-stage medical device and biopharmaceutical company. It is engaged in developing a Nitric Oxide Generator and Delivery System. The company's principal product is AirNOvent which is in clinical stage. Beyond Air Inc., formerly known as AIT Therapeutics Inc., is based in Garden...

See More

Key Turning Points

2nd Resistance Point 5.96
1st Resistance Point 5.60
Last Price 5.24
1st Support Level 5.03
2nd Support Level 4.82

See More

52-Week High 6.25
Last Price 5.24
Fibonacci 61.8% 5.05
Fibonacci 50% 4.68
Fibonacci 38.2% 4.31
52-Week Low 3.11

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar